EP Patent

EP1471911A1 — Novel crystalline forms of gatifloxacin

Assigned to Teva Pharmaceutical Industries Ltd · Expires 2004-11-03 · 22y expired

What this patent protects

Provided are two novel crystalline forms of gatifloxacin, denominated form O and form V, methods for their preparation and pharmaceutical compositions thereof.

USPTO Abstract

Provided are two novel crystalline forms of gatifloxacin, denominated form O and form V, methods for their preparation and pharmaceutical compositions thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP1471911A1
Jurisdiction
EP
Classification
—
Expires
2004-11-03
Drug substance claim
No
Drug product claim
No
Assignee
Teva Pharmaceutical Industries Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.